COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #121
Source   PDF   Share   Tweet
See all 181 studies
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Laplana et al., medRxiv, doi:10.1101/2020.09.03.20158121 (Preprint)
Lack of protective effect of ch loroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
Survey of 319 autoimmune disease patients taking C Q/HC Q with 5.3% COVID-19 incidence, compared to a control group from the general population (matched on age, sex, and region, but not adjusted for autoimmune disease), with 3.4% incidence.
It not clear why authors did not compare with autoimmune patients not on C Q/HC Q. Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [1], which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure. If we adjust for the different baseline risk, the result becomes RR 0.36, p<0.001, suggesting a substantial benefit for HC Q/C Q treatment (as shown in other studies).
There may also be significant survey bias - those experiencing COVID-19 may be more likely to respond to the survey.
Authors note that they "could not eliminate completely the possibility of some bias due to the intrinsic condition of the individuals within the treatment group that are undergoing ch loroquine or derivative drug treatment due to other diseases that alter their health status and may have different comorbidities", however they could account for one significant bias by comparing with matched autoimmune disease patients.
COVID-19 case, ↑56.0%, p=0.24
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.